Pellissier JM - Search Results

1

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

White RR, Lenhart G, Singhal PK, Insinga RP, Itzler RF, Pellissier JM, Segraves AW. White RR, et al. Among authors: pellissier jm. Pharmacoeconomics. 2009;27(9):781-92. doi: 10.2165/11317560-000000000-00000. Pharmacoeconomics. 2009. PMID: 19757871

2

Health care utilization and cost burden of herpes zoster in a community population.

Yawn BP, Itzler RF, Wollan PC, Pellissier JM, Sy LS, Saddier P. Yawn BP, et al. Among authors: pellissier jm. Mayo Clin Proc. 2009 Sep;84(9):787-94. doi: 10.1016/S0025-6196(11)60488-6. Mayo Clin Proc. 2009. PMID: 19720776 Free PMC article.

3

The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.

Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. Brisson M, et al. Among authors: pellissier jm. Hum Vaccin. 2008 May-Jun;4(3):238-45. doi: 10.4161/hv.4.3.5686. Epub 2010 May 25. Hum Vaccin. 2008. PMID: 18382137

4

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Pellissier JM, Brisson M, Levin MJ. Pellissier JM, et al. Vaccine. 2007 Nov 28;25(49):8326-37. doi: 10.1016/j.vaccine.2007.09.066. Epub 2007 Oct 17. Vaccine. 2007. PMID: 17980938

5

The incidence of herpes zoster in a United States administrative database.

Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. Insinga RP, et al. Among authors: pellissier jm. J Gen Intern Med. 2005 Aug;20(8):748-53. doi: 10.1111/j.1525-1497.2005.0150.x. J Gen Intern Med. 2005. PMID: 16050886 Free PMC article.

6

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM. Insinga RP, et al. Among authors: pellissier jm. Pharmacoeconomics. 2007;25(2):155-69. doi: 10.2165/00019053-200725020-00007. Pharmacoeconomics. 2007. PMID: 17249857

7

Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age.

Li X, Zhang JH, Betts RF, Morrison VA, Xu R, Itzler RF, Acosta CJ, Dasbach EJ, Pellissier JM, Johnson GR, Chan IS. Li X, et al. Among authors: pellissier jm. Vaccine. 2015 Mar 17;33(12):1499-505. doi: 10.1016/j.vaccine.2014.10.039. Epub 2014 Nov 6. Vaccine. 2015. PMID: 25444784

8

Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study.

Jönsson L, Justo N, Musayev A, Krishna A, Burke T, Pellissier J, Judson I, Staddon A, Blay JY. Jönsson L, et al. Eur J Cancer Care (Engl). 2016 May;25(3):466-77. doi: 10.1111/ecc.12322. Epub 2015 Apr 28. Eur J Cancer Care (Engl). 2016. PMID: 25923192

9

Work and productivity loss related to herpes zoster.

Singhal PK, Makin C, Pellissier J, Sy L, White R, Saddier P. Singhal PK, et al. J Med Econ. 2011;14(5):639-45. doi: 10.3111/13696998.2011.607482. Epub 2011 Aug 13. J Med Econ. 2011. PMID: 21838599

10

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S. Moore A, et al. Pharmacoeconomics. 2004;22(10):643-60. doi: 10.2165/00019053-200422100-00003. Pharmacoeconomics. 2004. PMID: 15244490

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results